Skip to main content
Shedir Pharma Group logo

Shedir Pharma Group — Investor Relations & Filings

Ticker · SHE ISIN · IT0005379620 LEI · 81560092B300849E9017 XMIL Manufacturing
Open in API
Filings indexed 124 across all filing types
Latest filing 2020-04-29 AGM Information
Country IT Italy
Listing XMIL SHE

About Shedir Pharma Group

https://www.shedirpharmagroup.com

Shedir Pharma Group specializes in the research, development, formulation, and commercialization of health and wellness products. The company's portfolio encompasses nutraceuticals, dermocosmetics, medical devices, and pharmaceuticals. A key focus is on innovation, resulting in the creation of unique and patented product formulations that cover approximately 15 therapeutic areas. The group operates through specialized subsidiaries that manage the entire product lifecycle, from initial research and intellectual property to marketing and distribution. Products are offered in various forms, such as capsules, tablets, powders, liquids, and gels, targeting professionals in the medical and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
Assemblea ordinaria degli azionisti del 29 aprile 2020
AGM Information Classification · 98% confidence The document is a press release titled "Assemblea ordinaria degli azionisti del 29 aprile 2020" (Ordinary Shareholders' Meeting of April 29, 2020). It details the resolutions passed during the meeting, specifically the approval of the 2019 Financial Statements (Bilancio d'Esercizio) and the determination of director compensation. While it discusses financial results (like the approval of the balance sheet), the primary purpose and format suggest it is an announcement related to a shareholder meeting and its outcomes, rather than the full Annual Report (10-K) or a standalone Audit Report (AR). The key actions relate to shareholder governance (approving financials, setting compensation). Since it is an announcement of the results of a general meeting, the most fitting category is AGM Information (AGM-R), as it directly reports on the proceedings and outcomes of the Ordinary General Meeting.
2020-04-29 Italian
Il Gruppo ottiene la concessione di otto nuovi brevetti italiani - Nel primo trimestre 2020 i prodotti coperti da brevetto crescono del 42%
Regulatory Filings Classification · 99% confidence The document is titled 'COMUNICATO STAMPA' (Press Release) and announces specific business news: the granting of eight new Italian patents and the corresponding growth in sales for patent-covered products in Q1 2020. It includes quotes from the CEO and provides company background. This format is characteristic of an initial announcement of significant, non-periodic business developments, often released via regulatory channels (indicated by the 'Informazione Regolamentata' header and 'REGEM' tipologia). Since it is a press release announcing operational achievements rather than formal financial results (ER/IR), management discussion (MDA), or a general regulatory filing (RNS), the most fitting category is Earnings Release (ER) if it contained financial highlights, or Regulatory Filing (RNS) if it's a general announcement. Given the focus on operational achievements (patents and sales growth metrics), it strongly resembles an Earnings Release (ER) which often includes key operational metrics alongside financial ones, or a specific announcement that falls under the general regulatory umbrella. However, since the core content is a press release detailing operational success and growth figures, and it is not a full financial report (10-K, IR), nor a management discussion (MDA), it functions as an initial release of performance-related information. In the context of Italian regulatory filings, this type of announcement often precedes or accompanies a formal financial report. Given the options, and the fact that it is a formal communication about business performance highlights (patent success and sales growth), 'ER' (Earnings Release) is plausible, but 'RNS' (Regulatory Filings) is the safest general category for non-standard, mandatory disclosures like this one, especially since it's structured as a formal regulatory information release ('Informazione Regolamentata'). Since the content is a press release announcing operational achievements and growth metrics, and not a full financial statement, I will classify it as a Regulatory Filing (RNS) as it is a formal, non-standard disclosure made through the regulated channel, or potentially an ER if the growth metrics are considered the 'highlights'. Given the structure and the 'Informazione Regolamentata' header, RNS is the most appropriate fallback for a specific operational announcement that isn't a core financial report or management discussion.
2020-04-28 Italian
Avviso di deposito della Relazione Finanziaria Annuale 2019 e della documentazione assembleare
Report Publication Announcement Classification · 99% confidence The document is a formal communication titled "Avviso di deposito della Relazione Finanziaria Annuale 2019 e della documentazione assembleare" (Notice of filing of the 2019 Annual Financial Report and assembly documentation). The key phrase is "Avviso di deposito" (Notice of filing/deposit) and the text explicitly states that the Annual Financial Report (Bilancio di esercizio e consolidato al 31 dicembre 2019) and related assembly documentation are being made available to the public at the registered office and on the website. This structure—a short announcement informing the market that a major report (the Annual Report) is now available—perfectly matches the definition of a Report Publication Announcement (RPA). Although the content relates to the Annual Report (10-K), the document itself is the notice of publication, not the full report itself, adhering to the 'MENU VS MEAL' rule.
2020-04-14 Italian
Pubblicazione dell’Avviso di Convocazione dell’Assemblea Ordinaria degli Azionisti di Shedir Pharma Group S.p.A.
AGM Information Classification · 99% confidence The document is an official communication titled "Pubblicazione dell'Avviso di Convocazione dell'Assemblea Ordinaria degli Azionisti di Shedir Pharma Group S.p.A." (Publication of the Notice of Convocation of the Ordinary Shareholders' Meeting). It details the date, time, location (with provisions for virtual attendance due to COVID-19), and the specific agenda items for the upcoming Shareholders' Meeting (e.g., approval of 2019 financial statements, authorization for share buybacks, determination of board compensation). This document serves to formally announce and provide details for a general meeting of shareholders, which aligns perfectly with the purpose of an AGM-related filing, specifically the notice of the meeting itself. While it relates to the AGM, the core function is the formal notice/convocation, which is often closely associated with AGM materials or Proxy Statements (DEF 14A/PSI). However, since the document is the *notice* of the meeting and its agenda, and it is not the proxy statement itself (PSI) nor the voting results (DVA), the most appropriate classification for the formal announcement of the Annual General Meeting proceedings is AGM-R (AGM Information/Materials). The length (12,602 chars) confirms it is the full notice, not just a brief announcement of publication (RPA).
2020-04-14 Italian
Ricavi in crescita nel 2019 per entrambe le divisioni del Gruppo
Earnings Release Classification · 99% confidence The document is a press release ("COMUNICATO STAMPA") from Shedir Pharma Group S.p.A. dated March 27, 2020, detailing financial results for the year ended December 31, 2019. It explicitly mentions key figures like Consolidated Revenues, Adjusted EBITDA, Adjusted Net Income, and Net Financial Position, and includes detailed comparative tables of economic data. This content structure—a formal announcement of period-end financial performance highlights—aligns perfectly with the definition of an Earnings Release (ER). Although it discusses the annual period (2019), it is a summary announcement, not the full Annual Report (10-K). The document length is substantial (45k chars), but its format is that of a press release summarizing results, not the comprehensive filing itself. FY 2019
2020-03-27 Italian
Ottenimento due nuovi brevetti italiani
Regulatory Filings Classification · 95% confidence The document is a press release dated January 31, 2020, announcing that Shedir Pharma Group S.p.A. has obtained two new Italian patents (Banzinact® and Visiopressin®). This type of announcement, detailing specific corporate achievements, product development milestones, or legal/IP updates, is generally classified as a general regulatory announcement or a specific corporate update. Since there is no specific category for 'Patent Grant Announcement', and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory news. It is not a Report Publication Announcement (RPA) because it is announcing an event (patent grant), not the publication of a previously mentioned report.
2020-01-31 Italian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.